We serve Chemical Name:4,6-Dibromodibenzofuran CAS:201138-91-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4,6-Dibromodibenzofuran
CAS.NO:201138-91-2
Synonyms:4,6-dibromo-dibenzofurane;Dibenzofuran,4,6-dibromo;4,6-Dibromodibenzo[b,d]furan;Dibenzofuran, 4,6-dibromo-;4,6-dibromo-dibenzofuran
Molecular Formula:C12H6Br2O
Molecular Weight:325.983
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:396.0±22.0 °C at 760 mmHg
Density:1.9±0.1 g/cm3
Index of Refraction:1.739
PSA:13.14000
Exact Mass:323.878540
LogP:5.66
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,6-dibromo-dibenzofurane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,6-dibromo-dibenzofuran physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dibenzofuran, 4,6-dibromo- Use and application,4,6-Dibromodibenzo[b,d]furan technical grade,usp/ep/jp grade.
Related News: AZ’s chief financial officer and incoming Alexion head Marc Dunoyer acknowledged that the reimbursement infrastructure for rare disease drugs in China isn’t as advanced as it is in many developed economies. The rare disease market in China is still small, but there’s a growing recognition of its importance from authorities, he added. O-phenyl N-methyl-P-(1-methyl-2-methylenehydrazineyl)phosphonamidothioate manufacturers This scheme has a total outlay of Rs. 6,940 crore for the entire period. The applications under four different target segments were invited on November 30, 2020. Of the 215 applications, 36 products across the 4 target segments were granted. 3-(4-chloro-2,6-dimethylphenyl)-1-(4-chlorobenzyl)-1-(3,3-dimethylbutyl)urea suppliers A new post-hoc analysis of pooled data from the TULIP phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures each, compared to placebo, in patients with moderate to severe systemic lupus erythematosus (SLE). 4,7-diamino-2-morpholin-4-yl-pteridine-6-carboxylic acid amide vendor & factory.
